about
Behavioural traits propagate across generations via segregated iterative-somatic and gametic epigenetic mechanisms.Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptorsThe activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activitySerotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.Functional Rescue of Dopaminergic Neuron Loss in Parkinson's Disease Mice After Transplantation of Hematopoietic Stem and Progenitor Cells.Mitofusin 2 in POMC neurons connects ER stress with leptin resistance and energy imbalance.Catecholamine/Serotonin interactions: systems thinking for brain function and diseaseNovel therapeutic strategies in major depression: focus on RNAi and ketamine.A functional leptin system is essential for sodium tungstate antiobesity action.Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs.Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs.The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex.Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.Synaptic regulator α-synuclein in dopaminergic fibers is essentially required for the maintenance of subependymal neural stem cells.Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies.5-HT2A receptors are involved in cognitive but not antidepressant effects of fluoxetine.Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder.Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions.Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.Reduced α-MSH Underlies Hypothalamic ER-Stress-Induced Hepatic Gluconeogenesis.Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.Overexpression of TFEB Drives a Pleiotropic Neurotrophic Effect and Prevents Parkinson's Disease-Related Neurodegeneration.New antidepressant strategy based on acute siRNA silencing of 5-HT1A autoreceptorsBrain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesisSelective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for DepressionRegionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice
P50
Q27317789-EDC74610-EF94-478F-868A-BC03B8E4DD41Q28273285-D07D0A5A-1894-489E-9588-18EA6B07B6CFQ28281024-189F2BE5-EF28-4002-9475-AF57C724E2F4Q34350194-06D75C8D-9B20-416F-9AF1-3E57F883626FQ37034654-AC7F1D79-0375-40ED-B847-71149D43AF7CQ37339111-9BB72856-4A44-4F1B-8CD0-A76546C66C50Q37518766-213D7F97-D1E2-4406-A70B-CB83E8132695Q38158132-B8EB5953-0304-4444-9E89-8A484D5D6908Q38360162-A9FA19AC-0C34-4E63-9DEE-3EB4317C3022Q42751805-7C524CE5-3F9C-43B1-B00A-871A2767260BQ43088711-F1A44098-94F5-40D3-838D-0202FEC1E108Q44574108-39F8BACA-958D-4BD7-BDDA-76FBBD5F3EFAQ44658068-09C30290-9151-4D6F-A099-2AD43393F4F2Q46506812-EB849AF7-2520-4B90-BAC7-CE1532E8206CQ47259722-84F97732-7880-41C5-9506-5B9F6DAC81EDQ47317693-C78C6241-AA4D-46E5-8E3A-8A267B17510BQ47570731-54A45AEE-0A40-443B-898A-A4E3FFBD1B70Q47709353-A1C1CD60-FFF0-4351-938E-8541051AC801Q47862908-83F2D1F0-C5BB-4F6F-A9CF-D7F3D2D06E0BQ48093265-CC019469-C9B5-4E1B-960F-D7E368A021E6Q48432408-C3520AF5-6BBC-4F3D-89AA-C9C6E8056126Q48487356-EF884EA0-BDB2-4C2E-8B4F-AE76FAD4ABE1Q50282841-4CF2D833-A5AA-4BDD-97A0-ECC70DE838F2Q50440713-301EF030-C725-4F51-95E4-BEEDD07E7163Q52662683-40516D7C-B62B-4F09-A55D-A9C4457C6103Q53823687-80B35F33-9284-4A10-96F6-9851E285CA13Q63466775-6A76447B-B3D8-4DA5-BA5D-B021856AEB31Q64122735-0AC13336-28D2-4150-8023-8DF81D1D8C00Q90830373-BFCF6F25-A152-46F8-8162-A3D92878A4C1Q91012639-6421D452-8942-4A61-87AF-D8A7F61558E1
P50
description
researcher ORCID ID = 0000-0002-2069-9192
@en
wetenschapper
@nl
name
Analía Bortolozzi
@ast
Analía Bortolozzi
@en
Analía Bortolozzi
@es
Analía Bortolozzi
@nl
type
label
Analía Bortolozzi
@ast
Analía Bortolozzi
@en
Analía Bortolozzi
@es
Analía Bortolozzi
@nl
altLabel
Analia Bortolozzi Biassoni
@en
prefLabel
Analía Bortolozzi
@ast
Analía Bortolozzi
@en
Analía Bortolozzi
@es
Analía Bortolozzi
@nl
P1053
R-6159-2018
P106
P1153
6603505981
P21
P2798
P31
P496
0000-0002-2069-9192